1084 related articles for article (PubMed ID: 27456970)
1. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
2. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
[TBL] [Abstract][Full Text] [Related]
3. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
[TBL] [Abstract][Full Text] [Related]
6. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
[TBL] [Abstract][Full Text] [Related]
7. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
[TBL] [Abstract][Full Text] [Related]
8. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
10. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
[TBL] [Abstract][Full Text] [Related]
11. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
[TBL] [Abstract][Full Text] [Related]
13. Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases.
Sanches SM; Braun AC; Calsavara VF; Barbosa PNVP; Chinen LTD
Clinics (Sao Paulo); 2021; 76():e2971. PubMed ID: 34644733
[TBL] [Abstract][Full Text] [Related]
14. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.
Aktas B; Müller V; Tewes M; Zeitz J; Kasimir-Bauer S; Loehberg CR; Rack B; Schneeweiss A; Fehm T
Gynecol Oncol; 2011 Aug; 122(2):356-60. PubMed ID: 21605893
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
16. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers characterization of circulating tumour cells in breast cancer patients.
Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.
Aaltonen KE; Novosadová V; Bendahl PO; Graffman C; Larsson AM; Rydén L
Oncotarget; 2017 Jul; 8(28):45544-45565. PubMed ID: 28489591
[TBL] [Abstract][Full Text] [Related]
19. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
20. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
